De novo infection |
γH2AX |
LANA |
Episome persistence |
Jha et al., 2013
|
|
γH2AX, ATM |
? |
Establishment of latency |
Singh et al., 2014
|
Latent |
PARP1 |
TR, LANA |
Negative for virus maintenance |
Ohsaki et al., 2004
|
|
ATM, Chk2, γH2AX, p53 |
v-cyclin |
Oncogenic |
Koopal et al., 2007
|
|
DNA-PK, Ku70/80 |
LANA |
Negative for virus maintenance |
Cha et al., 2010
|
|
Chk2 |
LANA |
Protection from G2/M cell cycle arrest |
Kumar et al., 2014
|
|
GADD45B |
miRNA-K9 |
Anti-apoptotic, Protection from cell cycle arrest |
Liu et al., 2017
|
|
MRN |
cytoplasmic LANA (LANA⊿N) |
Modulation of an innate immune signaling pathway |
Mariggiò et al., 2017
|
Lytic |
PARP1 |
RTA |
Abortive lytic replication |
Gwack et al., 2003
|
|
ATM, p53 |
vIRF1 |
Downregulation of DDR for viral replication |
Shin et al., 2006
|
|
PARP1 |
ori-Lyt |
Positive for lytic DNA replication |
Wang et al., 2008
|
|
Ku70/80, DNA-PK, MSH2/6 |
ori-Lyt |
Supportive for lytic DNA replication |
Wang et al., 2008
|
|
TIP60 |
ORF36 |
Positive for lytic gene expression |
Li et al., 2011
|
|
γH2AX, Mre11, Rad50, Ku70/80, DNA-PK, PARP1, XRCC1, DNA ligase 3 |
ORF57 |
Genomic instability |
Jackson et al., 2014
|
|
RPA, Mre11 |
lytic replication foci |
Positive for viral DNA synthesis |
Hollingworth et al., 2015
|
|
DNA-PK, Ku80 |
lytic replication compartments |
Negative for viral DNA replication |
Hollingworth et al., 2017
|
|
MRN |
lytic replication compartments |
Positive for viral DNA replication |
Hollingworth et al., 2017
|